Personalised blueprint of intestinal health

The miGut-Health consortium aims to develop a personalized blueprint of intestinal health to predict and prevent inflammatory bowel disease. The overall goal is to deliver interdisciplinary solutions (molecular, nutritional, eHealth and patient engagement/empowerment level) for health promotion and disease prevention that would enable active patient engagement in health and self-care management. Taking on this mission, miGut-Health pursues the following strategic goals:

 – To integrate state-of-the-art omics (molecular, clinical, nutrition, social and environmental) for identification of actionable biomarkers, risk and health promoting factors linked to health-to disease transition in the general population, IBD high risk persons, as well as IBD patients.

 – To perform systems-level analyses of chronic inflammation by applying integrative models from omics and clinical data to predict risk for health-to-disease transition in IBD.

– To perform a proof-of-concept controlled clinical trial studying a nutrient elimination diet (here: gluten-free diet) and its impact on intestinal inflammation in IBD patients and high-risk individuals.

 – To exploit the impact of microbiome-derived diet-associated metabolites on gut inflammation reversion and restoration of barrier integrity and function using an innovative co-culture system of primary human intestinal organoids and sorted immune cell subsets.

 – To develop and apply novel technologies (sensors, mobile apps) to dynamically monitor individual nutrition as well as physical activity and principal health status.

– To implement a patient-centered approach for personalized health and self-care engagement targeted at IBD patients, individuals at risk for IBD and the general population as well as tools for health-care professionals.

Expected outcomes in miGut-Health:

– Biomarkers and prediction models that will enable researchers and medical professionals understand the chronic inflammation factors triggering the health-to-disease transition.

– Personalized molecular, life-style and nutrition-based health indicators and health tracking e-tools for health care professionals and citizens enabling to improve the health outcomes.

– Health care professionals will gain scientifically validated data on omics, dietary and lifestyle factors and clinically applicable biomarkers of health-to-disease transition. Outcomes of multidimensional data analysis will be used for development of tailored personalised guidelines for individual engagement and chronic disease prevention strategies.- Blueprint for personalized health engagement initiatives and eHealth tools will serve to better gather information on citizen health status, inform and engage citizens to maintain and improve their health and, therefore, will actively sustain engagement of IBD patients and high-risk individuals in health and prevention initiatives.

PROJECT PARTNERS

• UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN
• CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
• UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
• ACADEMISCH ZIEKENHUIS GRONINGEN
• WEIZMANN INSTITUTE OF SCIENCE
• UNIVERSITA CATTOLICA DEL SACRO CUORE
• EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
• OREBRO UNIVERSITY
• REGION HOVEDSTADEN
• EUROPEAN FEDERATION OF CROHN’S AND ULCERATIVE COLITIS ASSOCIATIONS
• ECOLE POLYTECHNIQUE FEDERALE DE LAUSANN